|
1
|
Gonzalez FM, Fries EM, Cude-Woods C, Bailey T, Blatnik M, Broussard LJ, Callahan NB, Choi JH, Clayton SM, Currie SA, Dawid M, Dees EB, Filippone BW, Fox W, Geltenbort P, George E, Hayen L, Hickerson KP, Hoffbauer MA, Hoffman K, Holley AT, Ito TM, Komives A, Liu CY, Makela M, Morris CL, Musedinovic R, O'Shaughnessy C, Pattie RW, Ramsey J, Salvat DJ, Saunders A, Sharapov EI, Slutsky S, Su V, Sun X, Swank C, Tang Z, Uhrich W, Vanderwerp J, Walstrom P, Wang Z, Wei W, Young AR. Improved Neutron Lifetime Measurement with UCNτ. Phys Rev Lett 2021; 127:162501. [PMID: 34723594 DOI: 10.1103/physrevlett.127.162501] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Accepted: 07/20/2021] [Indexed: 06/13/2023]
Abstract
We report an improved measurement of the free neutron lifetime τ_{n} using the UCNτ apparatus at the Los Alamos Neutron Science Center. We count a total of approximately 38×10^{6} surviving ultracold neutrons (UCNs) after storing in UCNτ's magnetogravitational trap over two data acquisition campaigns in 2017 and 2018. We extract τ_{n} from three blinded, independent analyses by both pairing long and short storage time runs to find a set of replicate τ_{n} measurements and by performing a global likelihood fit to all data while self-consistently incorporating the β-decay lifetime. Both techniques achieve consistent results and find a value τ_{n}=877.75±0.28_{stat}+0.22/-0.16_{syst} s. With this sensitivity, neutron lifetime experiments now directly address the impact of recent refinements in our understanding of the standard model for neutron decay.
Collapse
Affiliation(s)
- F M Gonzalez
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
- Center for Exploration of Energy and Matter, Indiana University, Bloomington, Indiana 47405, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - E M Fries
- Kellogg Radiation Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - C Cude-Woods
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - T Bailey
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - M Blatnik
- Kellogg Radiation Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - L J Broussard
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - N B Callahan
- Argonne National Laboratory, Lemont, Illinois 60439, USA
| | - J H Choi
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - S M Clayton
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S A Currie
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - M Dawid
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
- Center for Exploration of Energy and Matter, Indiana University, Bloomington, Indiana 47405, USA
| | - E B Dees
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - B W Filippone
- Kellogg Radiation Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - W Fox
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
- Center for Exploration of Energy and Matter, Indiana University, Bloomington, Indiana 47405, USA
| | - P Geltenbort
- Institut Laue-Langevin, CS 20156, 38042 Grenoble Cedex 9, France
| | - E George
- Tennessee Technological University, Cookeville, Tennessee 38505, USA
| | - L Hayen
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - K P Hickerson
- Kellogg Radiation Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - M A Hoffbauer
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - K Hoffman
- Tennessee Technological University, Cookeville, Tennessee 38505, USA
| | - A T Holley
- Tennessee Technological University, Cookeville, Tennessee 38505, USA
| | - T M Ito
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - A Komives
- DePauw University, Greencastle, Indiana 46135, USA
| | - C-Y Liu
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
- Center for Exploration of Energy and Matter, Indiana University, Bloomington, Indiana 47405, USA
| | - M Makela
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - C L Morris
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - R Musedinovic
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - C O'Shaughnessy
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - R W Pattie
- East Tennessee State University, Johnson City, Tennessee 37614, USA
| | - J Ramsey
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - D J Salvat
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
- Center for Exploration of Energy and Matter, Indiana University, Bloomington, Indiana 47405, USA
| | - A Saunders
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - E I Sharapov
- Joint Institute for Nuclear Research, 141980 Dubna, Russia
| | - S Slutsky
- Kellogg Radiation Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - V Su
- Kellogg Radiation Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - X Sun
- Kellogg Radiation Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - C Swank
- Kellogg Radiation Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - Z Tang
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - W Uhrich
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J Vanderwerp
- Department of Physics, Indiana University, Bloomington, Indiana 47405, USA
- Center for Exploration of Energy and Matter, Indiana University, Bloomington, Indiana 47405, USA
| | - P Walstrom
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - Z Wang
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - W Wei
- Kellogg Radiation Laboratory, California Institute of Technology, Pasadena, California 91125, USA
| | - A R Young
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| |
Collapse
|
|
2
|
Kirtane AJ, Yeung AC, Ball M, Carr J, O'Shaughnessy C, Mauri L, Liu M, Leon MB. Long‐term (5‐year) clinical evaluation of the Resolute zotarolimus‐eluting coronary stent: The RESOLUTE US clinical trial. Catheter Cardiovasc Interv 2019; 95:1067-1073. [DOI: 10.1002/ccd.28392] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2019] [Revised: 06/26/2019] [Accepted: 06/27/2019] [Indexed: 11/11/2022]
Affiliation(s)
- Ajay J. Kirtane
- NewYork‐Presbyterian Hospital/Columbia University Medical Center New York New York
- Clinical Trials CenterCardiovascular Research Foundation New York New York
| | - Alan C. Yeung
- Stanford University School of Medicine Stanford California
| | | | - Jeffrey Carr
- Tyler Cardiac and Endovascular Center and East Texas Medical Center Tyler Texas
| | | | - Laura Mauri
- Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts
| | | | - Martin B. Leon
- NewYork‐Presbyterian Hospital/Columbia University Medical Center New York New York
- Clinical Trials CenterCardiovascular Research Foundation New York New York
| |
Collapse
|
|
3
|
Alvis SI, Arnquist IJ, Avignone FT, Barabash AS, Barton CJ, Bertrand FE, Brudanin V, Busch M, Buuck M, Caldwell TS, Chan YD, Christofferson CD, Chu PH, Cuesta C, Detwiler JA, Dunagan C, Efremenko Y, Ejiri H, Elliott SR, Gilliss T, Giovanetti GK, Green MP, Gruszko J, Guinn IS, Guiseppe VE, Haufe CR, Hehn L, Henning R, Hoppe EW, Howe MA, Konovalov SI, Kouzes RT, Lopez AM, Martin RD, Massarczyk R, Meijer SJ, Mertens S, Myslik J, O'Shaughnessy C, Othman G, Pettus W, Poon AWP, Radford DC, Rager J, Reine AL, Rielage K, Robertson RGH, Ruof NW, Shanks B, Shirchenko M, Suriano AM, Tedeschi D, Varner RL, Vasilyev S, Vorren K, White BR, Wilkerson JF, Wiseman C, Xu W, Yakushev E, Yu CH, Yumatov V, Zhitnikov I, Zhu BX. First Limit on the Direct Detection of Lightly Ionizing Particles for Electric Charge as Low as e/1000 with the Majorana Demonstrator. Phys Rev Lett 2018; 120:211804. [PMID: 29883176 DOI: 10.1103/physrevlett.120.211804] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/30/2018] [Revised: 04/23/2018] [Indexed: 06/08/2023]
Abstract
The Majorana Demonstrator is an ultralow-background experiment searching for neutrinoless double-beta decay in ^{76}Ge. The heavily shielded array of germanium detectors, placed nearly a mile underground at the Sanford Underground Research Facility in Lead, South Dakota, also allows searches for new exotic physics. Free, relativistic, lightly ionizing particles with an electrical charge less than e are forbidden by the standard model but predicted by some of its extensions. If such particles exist, they might be detected in the Majorana Demonstrator by searching for multiple-detector events with individual-detector energy depositions down to 1 keV. This search is background-free, and no candidate events have been found in 285 days of data taking. New direct-detection limits are set for the flux of lightly ionizing particles for charges as low as e/1000.
Collapse
Affiliation(s)
- S I Alvis
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - I J Arnquist
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - F T Avignone
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - A S Barabash
- National Research Center "Kurchatov Institute" Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - C J Barton
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - F E Bertrand
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - V Brudanin
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - M Busch
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - M Buuck
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - T S Caldwell
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - Y-D Chan
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - C D Christofferson
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - P-H Chu
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - C Cuesta
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - J A Detwiler
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - C Dunagan
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - Yu Efremenko
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37916, USA
| | - H Ejiri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S R Elliott
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - T Gilliss
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - G K Giovanetti
- Department of Physics, Princeton University, Princeton, New Jersey 08544, USA
| | - M P Green
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
| | - J Gruszko
- Department of Physics, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - I S Guinn
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - V E Guiseppe
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - C R Haufe
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - L Hehn
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R Henning
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - E W Hoppe
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M A Howe
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - S I Konovalov
- National Research Center "Kurchatov Institute" Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - R T Kouzes
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - A M Lopez
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37916, USA
| | - R D Martin
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - R Massarczyk
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S J Meijer
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - S Mertens
- Max-Planck-Institut für Physik, München 80805, Germany
- Physik Department, Technische Universität, München 85748, Germany
| | - J Myslik
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - C O'Shaughnessy
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - G Othman
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - W Pettus
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - A W P Poon
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D C Radford
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - J Rager
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - A L Reine
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - K Rielage
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - R G H Robertson
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - N W Ruof
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - B Shanks
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - M Shirchenko
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - A M Suriano
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - D Tedeschi
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - R L Varner
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - S Vasilyev
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - K Vorren
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - B R White
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J F Wilkerson
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - C Wiseman
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - W Xu
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - E Yakushev
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - C-H Yu
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - V Yumatov
- National Research Center "Kurchatov Institute" Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - I Zhitnikov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - B X Zhu
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| |
Collapse
|
|
4
|
Aalseth CE, Abgrall N, Aguayo E, Alvis SI, Amman M, Arnquist IJ, Avignone FT, Back HO, Barabash AS, Barbeau PS, Barton CJ, Barton PJ, Bertrand FE, Bode T, Bos B, Boswell M, Bradley AW, Brodzinski RL, Brudanin V, Busch M, Buuck M, Caldwell AS, Caldwell TS, Chan YD, Christofferson CD, Chu PH, Collar JI, Combs DC, Cooper RJ, Cuesta C, Detwiler JA, Doe PJ, Dunmore JA, Efremenko Y, Ejiri H, Elliott SR, Fast JE, Finnerty P, Fraenkle FM, Fu Z, Fujikawa BK, Fuller E, Galindo-Uribarri A, Gehman VM, Gilliss T, Giovanetti GK, Goett J, Green MP, Gruszko J, Guinn IS, Guiseppe VE, Hallin AL, Haufe CR, Hehn L, Henning R, Hoppe EW, Hossbach TW, Howe MA, Jasinski BR, Johnson RA, Keeter KJ, Kephart JD, Kidd MF, Knecht A, Konovalov SI, Kouzes RT, LaFerriere BD, Leon J, Lesko KT, Leviner LE, Loach JC, Lopez AM, Luke PN, MacMullin J, MacMullin S, Marino MG, Martin RD, Massarczyk R, McDonald AB, Mei DM, Meijer SJ, Merriman JH, Mertens S, Miley HS, Miller ML, Myslik J, Orrell JL, O'Shaughnessy C, Othman G, Overman NR, Perumpilly G, Pettus W, Phillips DG, Poon AWP, Pushkin K, Radford DC, Rager J, Reeves JH, Reine AL, Rielage K, Robertson RGH, Ronquest MC, Ruof NW, Schubert AG, Shanks B, Shirchenko M, Snavely KJ, Snyder N, Steele D, Suriano AM, Tedeschi D, Tornow W, Trimble JE, Varner RL, Vasilyev S, Vetter K, Vorren K, White BR, Wilkerson JF, Wiseman C, Xu W, Yakushev E, Yaver H, Young AR, Yu CH, Yumatov V, Zhitnikov I, Zhu BX, Zimmermann S. Search for Neutrinoless Double-β Decay in ^{76}Ge with the Majorana Demonstrator. Phys Rev Lett 2018; 120:132502. [PMID: 29694188 DOI: 10.1103/physrevlett.120.132502] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/08/2017] [Revised: 01/09/2018] [Indexed: 06/08/2023]
Abstract
The Majorana Collaboration is operating an array of high purity Ge detectors to search for neutrinoless double-β decay in ^{76}Ge. The Majorana Demonstrator comprises 44.1 kg of Ge detectors (29.7 kg enriched in ^{76}Ge) split between two modules contained in a low background shield at the Sanford Underground Research Facility in Lead, South Dakota. Here we present results from data taken during construction, commissioning, and the start of full operations. We achieve unprecedented energy resolution of 2.5 keV FWHM at Q_{ββ} and a very low background with no observed candidate events in 9.95 kg yr of enriched Ge exposure, resulting in a lower limit on the half-life of 1.9×10^{25} yr (90% C.L.). This result constrains the effective Majorana neutrino mass to below 240-520 meV, depending on the matrix elements used. In our experimental configuration with the lowest background, the background is 4.0_{-2.5}^{+3.1} counts/(FWHM t yr).
Collapse
Affiliation(s)
- C E Aalseth
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - N Abgrall
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - E Aguayo
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - S I Alvis
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - M Amman
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - I J Arnquist
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - F T Avignone
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - H O Back
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - A S Barabash
- National Research Center "Kurchatov Institute" Institute for Theoretical and Experimental Physics, Moscow, 117218 Russia
| | - P S Barbeau
- Department of Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - C J Barton
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - P J Barton
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - F E Bertrand
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - T Bode
- Max-Planck-Institut für Physik, München, 80805 Germany
| | - B Bos
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - M Boswell
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - A W Bradley
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R L Brodzinski
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - V Brudanin
- Joint Institute for Nuclear Research, Dubna, 141980 Russia
| | - M Busch
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - M Buuck
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - A S Caldwell
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - T S Caldwell
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - Y-D Chan
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - C D Christofferson
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - P-H Chu
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J I Collar
- Department of Physics, University of Chicago, Chicago, Illinois 60637, USA
| | - D C Combs
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - R J Cooper
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - C Cuesta
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - J A Detwiler
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - P J Doe
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - J A Dunmore
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - Yu Efremenko
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37916, USA
| | - H Ejiri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S R Elliott
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J E Fast
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - P Finnerty
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - F M Fraenkle
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - Z Fu
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - B K Fujikawa
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - E Fuller
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | | | - V M Gehman
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - T Gilliss
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - G K Giovanetti
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
- Department of Physics, Princeton University, Princeton, New Jersey 08544, USA
| | - J Goett
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - M P Green
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - J Gruszko
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - I S Guinn
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - V E Guiseppe
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - A L Hallin
- Centre for Particle Physics, University of Alberta, Edmonton, Alberta T6G 2E1, Canada
| | - C R Haufe
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - L Hehn
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - R Henning
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - E W Hoppe
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - T W Hossbach
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M A Howe
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - B R Jasinski
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - R A Johnson
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - K J Keeter
- Department of Physics, Black Hills State University, Spearfish, South Dakota 57799, USA
| | - J D Kephart
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M F Kidd
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Tennessee Tech University, Cookeville, Tennessee 38505, USA
| | - A Knecht
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - S I Konovalov
- National Research Center "Kurchatov Institute" Institute for Theoretical and Experimental Physics, Moscow, 117218 Russia
| | - R T Kouzes
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - B D LaFerriere
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - J Leon
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - K T Lesko
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Department of Physics, University of California, Berkeley, California 94720, USA
| | - L E Leviner
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - J C Loach
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Shanghai Jiao Tong University, Shanghai 200240, China
| | - A M Lopez
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37916, USA
| | - P N Luke
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J MacMullin
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - S MacMullin
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - M G Marino
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - R D Martin
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - R Massarczyk
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - A B McDonald
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - D-M Mei
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S J Meijer
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - J H Merriman
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - S Mertens
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Max-Planck-Institut für Physik, München, 80805 Germany
- Physik Department and Excellence Cluster Universe, Technische Universität, München, 85748 Germany
| | - H S Miley
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - M L Miller
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - J Myslik
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J L Orrell
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - C O'Shaughnessy
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - G Othman
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - N R Overman
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - G Perumpilly
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - W Pettus
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - D G Phillips
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - A W P Poon
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - K Pushkin
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - D C Radford
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - J Rager
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - J H Reeves
- Pacific Northwest National Laboratory, Richland, Washington 99354, USA
| | - A L Reine
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - K Rielage
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - R G H Robertson
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - M C Ronquest
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - N W Ruof
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - A G Schubert
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - B Shanks
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - M Shirchenko
- Joint Institute for Nuclear Research, Dubna, 141980 Russia
| | - K J Snavely
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - N Snyder
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - D Steele
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - A M Suriano
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - D Tedeschi
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - W Tornow
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
| | - J E Trimble
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - R L Varner
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - S Vasilyev
- Joint Institute for Nuclear Research, Dubna, 141980 Russia
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37916, USA
| | - K Vetter
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
- Department of Nuclear Engineering, University of California, Berkeley, California 94720, USA
| | - K Vorren
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - B R White
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J F Wilkerson
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - C Wiseman
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - W Xu
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27514, USA
| | - E Yakushev
- Joint Institute for Nuclear Research, Dubna, 141980 Russia
| | - H Yaver
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - A R Young
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - C-H Yu
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830, USA
| | - V Yumatov
- National Research Center "Kurchatov Institute" Institute for Theoretical and Experimental Physics, Moscow, 117218 Russia
| | - I Zhitnikov
- Joint Institute for Nuclear Research, Dubna, 141980 Russia
| | - B X Zhu
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S Zimmermann
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| |
Collapse
|
|
5
|
Wong SC, Gammon R, Bachinsky W, O'Shaughnessy C, Leimbach W, Bernardo N, Cavros N, Jaff MR, Liu PY, Bergman G. The CLOSER trial: a multi-center study on the clinical safety and effectiveness of Closer TM VSS, a novel resorbable transfemoral vascular access sealing system. Catheter Cardiovasc Interv 2017; 90:798-805. [PMID: 28833996 DOI: 10.1002/ccd.27241] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/08/2016] [Revised: 05/18/2017] [Accepted: 07/22/2017] [Indexed: 11/08/2022]
Abstract
OBJECTIVES To evaluate the safety and effectiveness of the Closer Vascular Sealing System (VSS) against prespecified performance goals (PGs) in sealing femoral arterial access following 5-7 Fr procedures. BACKGROUND Inconsistent safety profiles, costs and learning curves of earlier generation vascular closure devices have limited their widespread use following transfemoral procedures. METHODS In this prospective single-arm, multi-center trial, we compared the clinical outcomes in patients undergoing 5-7 Fr transfemoral diagnostic or interventional procedures and access sites managed with Closer VSS against pre-specified PGs. The primary endpoints were time to hemostasis (TTH) and 30-day access site closure-related major complications; secondary endpoints included time to ambulation (TTA), time to discharge eligibility (TTDE), time to discharge (TTD), 30-day access site minor complications, procedure and device success. RESULTS A total of 220 subjects (49.5% interventional) were enrolled. The mean TTH was 1.78 ± 7.81 min in the intention to treat and 0.98 ± 3.71 min in the per protocol cohort. Median TTH was 0 min with immediate hemostasis achieved in 80.5% of subjects, mean TTA was 2.50 ± 1.05 hr, and mean TTDE was 2.83 ± 1.54 hr. Thirty-day follow-up was completed on 219 subjects. There were no access site closure-related major complications, minor complication rate was 0.0% for diagnostic and 2.75% for interventional procedures. CONCLUSIONS In patients undergoing 5-7 Fr transfemoral diagnostic and interventional procedures, the CLOSER Trial met both its primary effectiveness and safety PGs. Immediate hemostasis was achieved in the majority of patients without major complication.
Collapse
Affiliation(s)
- S Chiu Wong
- Division of Cardiology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York
| | | | | | | | | | - Nelson Bernardo
- Medstar Heart & Vascular Institute at Medstar Washington Hospital Center, Washington, District of Columbia
| | - Nick Cavros
- Cardiovascular Institute of the South, Lafayette, Louisiana
| | | | - Ping-Yu Liu
- Fred Hutchinson Cancer Research Center, Seattle, Washington
| | - Geoffrey Bergman
- Division of Cardiology, Weill Cornell Medical College/New York Presbyterian Hospital, New York, New York
| |
Collapse
|
|
6
|
Abgrall N, Arnquist IJ, Avignone FT, Barabash AS, Bertrand FE, Bradley AW, Brudanin V, Busch M, Buuck M, Caldwell TS, Chan YD, Christofferson CD, Chu PH, Cuesta C, Detwiler JA, Dunagan C, Efremenko Y, Ejiri H, Elliott SR, Gilliss T, Giovanetti GK, Goett J, Green MP, Gruszko J, Guinn IS, Guiseppe VE, Haufe CRS, Henning R, Hoppe EW, Howard S, Howe MA, Jasinski BR, Keeter KJ, Kidd MF, Konovalov SI, Kouzes RT, Lopez AM, MacMullin J, Martin RD, Massarczyk R, Meijer SJ, Mertens S, O'Shaughnessy C, Poon AWP, Radford DC, Rager J, Reine AL, Rielage K, Robertson RGH, Shanks B, Shirchenko M, Suriano AM, Tedeschi D, Trimble JE, Varner RL, Vasilyev S, Vetter K, Vorren K, White BR, Wilkerson JF, Wiseman C, Xu W, Yakushev E, Yu CH, Yumatov V, Zhitnikov I, Zhu BX. New Limits on Bosonic Dark Matter, Solar Axions, Pauli Exclusion Principle Violation, and Electron Decay from the Majorana Demonstrator. Phys Rev Lett 2017; 118:161801. [PMID: 28474933 DOI: 10.1103/physrevlett.118.161801] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/02/2016] [Indexed: 06/07/2023]
Abstract
We present new limits on exotic keV-scale physics based on 478 kg d of Majorana Demonstrator commissioning data. Constraints at the 90% confidence level are derived on bosonic dark matter (DM) and solar axion couplings, Pauli exclusion principle violating (PEPV) decay, and electron decay using monoenergetic peak signal limits above our background. Our most stringent DM constraints are set for 11.8 keV mass particles, limiting g_{Ae}<4.5×10^{-13} for pseudoscalars and (α^{'}/α)<9.7×10^{-28} for vectors. We also report a 14.4 keV solar axion coupling limit of g_{AN}^{eff}×g_{Ae}<3.8×10^{-17}, a 1/2β^{2}<8.5×10^{-48} limit on the strength of PEPV electron transitions, and a lower limit on the electron lifetime of τ_{e}>1.2×10^{24} yr for e^{-}→ invisible.
Collapse
Affiliation(s)
- N Abgrall
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - I J Arnquist
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - F T Avignone
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - A S Barabash
- National Research Center "Kurchatov Institute" Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - F E Bertrand
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - A W Bradley
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - V Brudanin
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - M Busch
- Department of Physics, Duke University, Durham, North Carolina 27708, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
| | - M Buuck
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - T S Caldwell
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - Y-D Chan
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - C D Christofferson
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - P-H Chu
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - C Cuesta
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - J A Detwiler
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - C Dunagan
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - Yu Efremenko
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - H Ejiri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S R Elliott
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - T Gilliss
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - G K Giovanetti
- Department of Physics, Princeton University, Princeton, New Jersey 08544, USA
| | - J Goett
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - M P Green
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics, North Carolina State University, Raleigh, North Carolina 27695, USA
| | - J Gruszko
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - I S Guinn
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - V E Guiseppe
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - C R S Haufe
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - R Henning
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - E W Hoppe
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - S Howard
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - M A Howe
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - B R Jasinski
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - K J Keeter
- Department of Physics, Black Hills State University, Spearfish, South Dakota 57799, USA
| | - M F Kidd
- Tennessee Tech University, Cookeville, Tennessee 38505, USA
| | - S I Konovalov
- National Research Center "Kurchatov Institute" Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - R T Kouzes
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - A M Lopez
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - J MacMullin
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - R D Martin
- Department of Physics, Engineering Physics and Astronomy, Queen's University, Kingston, Ontario K7L 3N6, Canada
| | - R Massarczyk
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S J Meijer
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - S Mertens
- Max-Planck-Institut für Physik, München 80805, Germany
- Physik Department and Excellence Cluster Universe, Technische Universität, München 80805, Germany
| | - C O'Shaughnessy
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - A W P Poon
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - D C Radford
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - J Rager
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - A L Reine
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - K Rielage
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - R G H Robertson
- Center for Experimental Nuclear Physics and Astrophysics, and Department of Physics, University of Washington, Seattle, Washington 98195, USA
| | - B Shanks
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - M Shirchenko
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - A M Suriano
- South Dakota School of Mines and Technology, Rapid City, South Dakota 57701, USA
| | - D Tedeschi
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - J E Trimble
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - R L Varner
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - S Vasilyev
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - K Vetter
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - K Vorren
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - B R White
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J F Wilkerson
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA
- Department of Physics and Astronomy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
| | - C Wiseman
- Department of Physics and Astronomy, University of South Carolina, Columbia, South Carolina 29208, USA
| | - W Xu
- Department of Physics, University of South Dakota, Vermillion, South Dakota 57069, USA
| | - E Yakushev
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - C-H Yu
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - V Yumatov
- National Research Center "Kurchatov Institute" Institute for Theoretical and Experimental Physics, Moscow 117218, Russia
| | - I Zhitnikov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - B X Zhu
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| |
Collapse
|
|
7
|
Wong SC, Gammon R, Bachinsky W, O'Shaughnessy C, Leimbach W, Bernardo N, Cavros N, Jaff M, Bergman G. TCT-369 The CLOSER Trial: A Multicenter Study on the Clinical Safety and Effectiveness of Closer™ VSS, a Novel Resorbable Transfemoral Vascular Access Sealing System. J Am Coll Cardiol 2016. [DOI: 10.1016/j.jacc.2016.09.502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
|
8
|
Agostini M, Allardt M, Andreotti E, Bakalyarov AM, Balata M, Barabanov I, Barnabé Heider M, Barros N, Baudis L, Bauer C, Becerici-Schmidt N, Bellotti E, Belogurov S, Belyaev ST, Benato G, Bettini A, Bezrukov L, Bode T, Brudanin V, Brugnera R, Budjáš D, Caldwell A, Cattadori C, Chernogorov A, Cossavella F, Demidova EV, Domula A, Egorov V, Falkenstein R, Ferella A, Freund K, Frodyma N, Gangapshev A, Garfagnini A, Gotti C, Grabmayr P, Gurentsov V, Gusev K, Guthikonda KK, Hampel W, Hegai A, Heisel M, Hemmer S, Heusser G, Hofmann W, Hult M, Inzhechik LV, Ioannucci L, Janicskó Csáthy J, Jochum J, Junker M, Kihm T, Kirpichnikov IV, Kirsch A, Klimenko A, Knöpfle KT, Kochetov O, Kornoukhov VN, Kuzminov VV, Laubenstein M, Lazzaro A, Lebedev VI, Lehnert B, Liao HY, Lindner M, Lippi I, Liu X, Lubashevskiy A, Lubsandorzhiev B, Lutter G, Macolino C, Machado AA, Majorovits B, Maneschg W, Misiaszek M, Nemchenok I, Nisi S, O'Shaughnessy C, Pandola L, Pelczar K, Pessina G, Pullia A, Riboldi S, Rumyantseva N, Sada C, Salathe M, Schmitt C, Schreiner J, Schulz O, Schwingenheuer B, Schönert S, Shevchik E, Shirchenko M, Simgen H, Smolnikov A, Stanco L, Strecker H, Tarka M, Ur CA, Vasenko AA, Volynets O, von Sturm K, Wagner V, Walter M, Wegmann A, Wester T, Wojcik M, Yanovich E, Zavarise P, Zhitnikov I, Zhukov SV, Zinatulina D, Zuber K, Zuzel G. Results on neutrinoless double-β decay of 76Ge from phase I of the GERDA experiment. Phys Rev Lett 2013; 111:122503. [PMID: 24093254 DOI: 10.1103/physrevlett.111.122503] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/17/2013] [Indexed: 06/02/2023]
Abstract
Neutrinoless double beta decay is a process that violates lepton number conservation. It is predicted to occur in extensions of the standard model of particle physics. This Letter reports the results from phase I of the Germanium Detector Array (GERDA) experiment at the Gran Sasso Laboratory (Italy) searching for neutrinoless double beta decay of the isotope (76)Ge. Data considered in the present analysis have been collected between November 2011 and May 2013 with a total exposure of 21.6 kg yr. A blind analysis is performed. The background index is about 1 × 10(-2) counts/(keV kg yr) after pulse shape discrimination. No signal is observed and a lower limit is derived for the half-life of neutrinoless double beta decay of (76)Ge, T(1/2)(0ν) >2.1 × 10(25) yr (90% C.L.). The combination with the results from the previous experiments with (76)Ge yields T(1/2)(0ν)>3.0 × 10(25) yr (90% C.L.).
Collapse
Affiliation(s)
- M Agostini
- Physik Department and Excellence Cluster Universe, Technische Universität München, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
9
|
Genereux P, Goldberg S, O'Shaughnessy C, Midei M, Siegel RM, Mintz GS, Cristea E, Dangas G, Lansky AJ, Mehran R, Stone GW. FIVE-YEAR FOLLOW-UP OF POLYTETRAFLUOROETHYLENE-COVERED STENTS COMPARED WITH BARE METAL STENTS IN AORTOCORONARY SAPHENOUS VEIN GRAFTS: THE RANDOMIZED BARRICADE TRIAL. J Am Coll Cardiol 2011. [DOI: 10.1016/s0735-1097(11)61621-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
|
10
|
Stone GW, Goldberg S, O'Shaughnessy C, Midei M, Siegel RM, Cristea E, Dangas G, Lansky AJ, Mehran R. 5-Year Follow-Up of Polytetrafluoroethylene-Covered Stents Compared With Bare-Metal Stents in Aortocoronary Saphenous Vein Grafts. JACC Cardiovasc Interv 2011; 4:300-9. [DOI: 10.1016/j.jcin.2010.11.013] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2010] [Accepted: 11/16/2010] [Indexed: 12/12/2022]
|
|
11
|
Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS, Popma JJ. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2010; 2:1208-18. [PMID: 20129547 DOI: 10.1016/j.jcin.2009.10.008] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2009] [Revised: 10/13/2009] [Accepted: 10/16/2009] [Indexed: 01/15/2023]
Abstract
OBJECTIVES The aim of this study was to assess, after 2 years of follow-up, the safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent (ZES) compared with a paclitaxel-eluting stent (PES) in patients with native coronary lesions. BACKGROUND Early drug-eluting stents were associated with a small but significant incidence of very late stent thrombosis (VLST), occurring >1 year after the index procedure. The ZES has shown encouraging results in clinical trials. METHODS The ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions), a randomized (1:1), single-blind, controlled trial (n = 1,548) compared ZES versus PES in patients with single de novo coronary lesions. Two-year follow-up was obtained in 96.0% of ZES and 95.4% of PES patients. The primary end point was target vessel failure (TVF), and safety end points included Academic Research Consortium-defined stent thrombosis. Economic end points analyzed included quality-adjusted survival, medical costs, and relative cost-effectiveness of ZES and PES. RESULTS The TVF at 2 years was similar in ZES and PES patients (11.1% vs. 13.1%, p = 0.232). There were fewer myocardial infarctions (MIs) in ZES patients (p = 0.022), due to fewer periprocedural non-Q-wave MIs and fewer late MIs between 1 and 2 years. Late MIs were associated with increased VLST (PES: 6 vs. ZES: 1; p = 0.069). Target lesion revascularization was similar comparing ZES with PES (5.9% vs. 4.6%; p = 0.295), especially in patients without planned angiographic follow-up (5.2% vs. 4.9%; p = 0.896). The cost-effectiveness of ZES and PES was similar. CONCLUSIONS After 2 years of follow-up, ZES demonstrated efficacy and cost-effectiveness comparable to PES, with fewer MIs and a trend toward less VLST. (The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions; NCT00217269).
Collapse
Affiliation(s)
- Martin B Leon
- Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York 10032, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
12
|
Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DS. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC Cardiovasc Interv 2010; 2:1248-59. [PMID: 20129552 DOI: 10.1016/j.jcin.2009.10.003] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2009] [Revised: 10/06/2009] [Accepted: 10/08/2009] [Indexed: 01/11/2023]
Abstract
OBJECTIVES The pivotal TAXUS IV (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent) trial evaluated the long-term safety and effectiveness of the paclitaxel-eluting stent (PES) compared with an otherwise identical bare-metal stent (BMS) in a relatively uncomplicated population of patients with a single de novo lesion in a native coronary vessel, treated between March and July 2002. BACKGROUND Long-term follow-up is required to determine whether the early safety and efficacy of drug-eluting stents are maintained. METHODS The primary end point of this prospective, randomized, double-blind trial was 9-month ischemia-driven target vessel revascularization (TVR) for PES versus the BMS control. Follow-up was complete in 1,230 (95.1%) of 1,294 randomized evaluable patients at 5 years. RESULTS Compared with BMS, PES significantly reduced TVR at 9 months (12.1% vs. 4.7%; p < 0.0001); this benefit was maintained through 5 years (27.4% vs. 16.9%; p < 0.0001), given comparable TVR rates for BMS and PES between years 1 and 5 (4.1%/year vs. 3.3%/year; respectively, p = 0.16). Similar patterns were observed for composite major adverse cardiac events (MACE) (32.8% BMS vs. 24.0% PES, p = 0.0001 at 5 years). Stent thrombosis was comparable for PES and BMS at 9 months (0.8% BMS vs. 0.8% PES; p = 0.98) and at 5 years (2.1% BMS vs. 2.2% PES, p = 0.87). The overall revascularization benefits of PES were consistent across multiple subgroups, including sex, diabetes, left anterior descending artery lesion location, reference vessel diameter, lesion length, and multiple stents. CONCLUSIONS These 5-year results demonstrate the long-term safety and sustained efficacy of PES compared with BMS in patients with noncomplex lesions. (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent; NCT00292474).
Collapse
Affiliation(s)
- Stephen G Ellis
- Cleveland Clinic, Department of Cardiology, Cleveland, Ohio 44195, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
13
|
Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas JS, Ball MW, Caputo RP, Jain A, Tolleson TR, Reen BM, Kirtane AJ, Fitzgerald PJ, Thompson K, Kandzari DE. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol 2010; 55:543-54. [PMID: 20152559 DOI: 10.1016/j.jacc.2009.08.067] [Citation(s) in RCA: 156] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2009] [Revised: 08/26/2009] [Accepted: 08/30/2009] [Indexed: 01/03/2023]
Abstract
OBJECTIVES The ENDEAVOR IV (Randomized Comparison of Zotarolimus-Eluting and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease) trial evaluated the safety and efficacy of the zotarolimus-eluting stent (ZES) compared with the paclitaxel-eluting stent (PES). BACKGROUND First-generation drug-eluting stents have reduced angiographic and clinical restenosis, but long-term safety remains controversial. A second-generation drug-eluting stent, which delivers zotarolimus, a potent antiproliferative agent, via a biocompatible phosphorylcholine polymer on a cobalt alloy thin-strut stent has shown promising experimental and early clinical results. METHODS This is a prospective, randomized (1:1), single-blind, controlled trial comparing outcomes of patients with single de novo coronary lesions treated with ZES or PES. The primary end point was noninferiority of 9-month target vessel failure defined as cardiac death, myocardial infarction, or target vessel revascularization. RESULTS Among a total of 1,548 patients assigned to ZES (n = 773) or PES (n = 775), at 9 months, ZES was noninferior to PES with rates of target vessel failure 6.6% versus 7.1%, respectively (p(noninferiority) < or = 0.001). There were fewer periprocedural myocardial infarctions with ZES (0.5% vs. 2.2%; p = 0.007), whereas at 12 months, there were no significant differences between groups in rates of cardiac death, myocardial infarction, target vessel revascularization, or stent thrombosis. Although incidence of 8-month binary angiographic in-segment restenosis was higher in patients treated with ZES versus PES (15.3% vs. 10.4%; p = 0.284), rates of 12-month target lesion revascularization were similar (4.5% vs. 3.2%; p = 0.228), especially in patients without planned angiographic follow-up (3.6% vs. 3.2%; p = 0.756). CONCLUSIONS These findings demonstrate that ZES has similar clinical safety and efficacy compared with PES in simple and medium complexity single de novo coronary lesions. (ENDEAVOR IV Clinical Trial; NCT00217269).
Collapse
Affiliation(s)
- Martin B Leon
- Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
14
|
Kirtane AJ, Patel R, O'Shaughnessy C, Overlie P, McLaurin B, Solomon S, Mauri L, Fitzgerald P, Popma JJ, Kandzari DE, Leon MB. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. JACC Cardiovasc Interv 2010; 2:967-76. [PMID: 19850257 DOI: 10.1016/j.jcin.2009.08.008] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2009] [Revised: 07/09/2009] [Accepted: 08/19/2009] [Indexed: 11/18/2022]
Abstract
OBJECTIVES The aim of this study was to examine outcomes related to the use of the Endeavor zotarolimus-eluting stent (ZES) (Medtronic CardioVascular, Santa Rosa, California) compared with the TAXUS paclitaxel-eluting stent (PES) (Boston Scientific Corp., Natick, Massachusetts) in the 477 patients with diabetes mellitus (DM) enrolled in the randomized ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease) trial. BACKGROUND Percutaneous coronary intervention (PCI) in diabetic patients is associated with increased rates of restenosis-related end points compared with PCI in nondiabetic patients. Although ZES has been associated with similar clinical efficacy compared with PES in the overall trial population of the ENDEAVOR IV trial, whether these results are maintained in the higher-risk restenosis subgroup of patients with DM has not been determined. METHODS Clinical and angiographic outcomes were compared according to randomized treatment assignment to either ZES or PES. RESULTS Baseline characteristics were similar among ZES (n = 241) and PES (n = 236) diabetic patients, with slightly longer lesion lengths in PES-treated patients (12.9 mm vs. 14.0 mm, p = 0.041). Among the 86 DM patients assigned to routine angiographic follow-up (18% of the overall DM cohort), in-stent percent diameter stenosis at 8 months was greater among ZES-treated patients (32.9 vs. 21.1, p = 0.023), with a trend toward higher in-stent late loss. One-year clinical outcomes were similar among DM patients treated with either ZES or PES (target vessel failure: 8.6% vs. 10.8%, p = 0.53; target lesion revascularization: 6.9% vs. 5.8%, p = 0.70; target vessel revascularization: 8.6% vs. 9.4%, p = 0.87). There were no significant interactions between DM status and stent type with respect to the outcomes measured, and the relative efficacy/safety of ZES and PES were similar among insulin- and noninsulin-requiring subgroups. CONCLUSIONS One-year clinical outcomes were similar among DM patients treated with ZES and PES in the ENDEAVOR IV trial. These findings parallel the overall trial results, which demonstrated similar efficacy and safety of ZES and PES for single de novo coronary lesions.
Collapse
Affiliation(s)
- Ajay J Kirtane
- Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
15
|
Popma JJ, Mauri L, O'Shaughnessy C, Overlie P, McLaurin B, Almonacid A, Kirtane A, Leon MB. Frequency and Clinical Consequences Associated With Sidebranch Occlusion During Stent Implantation Using Zotarolimus-Eluting and Paclitaxel-Eluting Coronary Stents. Circ Cardiovasc Interv 2009; 2:133-9. [DOI: 10.1161/circinterventions.108.832048] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Jeffrey J. Popma
- From the Department of Internal Medicine, Cardiology Divisions (J.J.P.) of the Beth Israel Deaconess Medical Center, Boston, Mass; Brigham and Women’s Hospital (L.M., A.A.), Boston, Mass; Elyria Memorial Hospital (C.S.), Elyria, Ohio; Lubbock Heart Hospital (P.O.), Lubbock, Tex; Anderson Medical Center (B.M.L.), Anderson, SC; and Columbia University Medical Center (A.K., M.B.L.), New York, NY
| | - Laura Mauri
- From the Department of Internal Medicine, Cardiology Divisions (J.J.P.) of the Beth Israel Deaconess Medical Center, Boston, Mass; Brigham and Women’s Hospital (L.M., A.A.), Boston, Mass; Elyria Memorial Hospital (C.S.), Elyria, Ohio; Lubbock Heart Hospital (P.O.), Lubbock, Tex; Anderson Medical Center (B.M.L.), Anderson, SC; and Columbia University Medical Center (A.K., M.B.L.), New York, NY
| | - Charles O'Shaughnessy
- From the Department of Internal Medicine, Cardiology Divisions (J.J.P.) of the Beth Israel Deaconess Medical Center, Boston, Mass; Brigham and Women’s Hospital (L.M., A.A.), Boston, Mass; Elyria Memorial Hospital (C.S.), Elyria, Ohio; Lubbock Heart Hospital (P.O.), Lubbock, Tex; Anderson Medical Center (B.M.L.), Anderson, SC; and Columbia University Medical Center (A.K., M.B.L.), New York, NY
| | - Paul Overlie
- From the Department of Internal Medicine, Cardiology Divisions (J.J.P.) of the Beth Israel Deaconess Medical Center, Boston, Mass; Brigham and Women’s Hospital (L.M., A.A.), Boston, Mass; Elyria Memorial Hospital (C.S.), Elyria, Ohio; Lubbock Heart Hospital (P.O.), Lubbock, Tex; Anderson Medical Center (B.M.L.), Anderson, SC; and Columbia University Medical Center (A.K., M.B.L.), New York, NY
| | - Brent McLaurin
- From the Department of Internal Medicine, Cardiology Divisions (J.J.P.) of the Beth Israel Deaconess Medical Center, Boston, Mass; Brigham and Women’s Hospital (L.M., A.A.), Boston, Mass; Elyria Memorial Hospital (C.S.), Elyria, Ohio; Lubbock Heart Hospital (P.O.), Lubbock, Tex; Anderson Medical Center (B.M.L.), Anderson, SC; and Columbia University Medical Center (A.K., M.B.L.), New York, NY
| | - Alexandra Almonacid
- From the Department of Internal Medicine, Cardiology Divisions (J.J.P.) of the Beth Israel Deaconess Medical Center, Boston, Mass; Brigham and Women’s Hospital (L.M., A.A.), Boston, Mass; Elyria Memorial Hospital (C.S.), Elyria, Ohio; Lubbock Heart Hospital (P.O.), Lubbock, Tex; Anderson Medical Center (B.M.L.), Anderson, SC; and Columbia University Medical Center (A.K., M.B.L.), New York, NY
| | - Ajay Kirtane
- From the Department of Internal Medicine, Cardiology Divisions (J.J.P.) of the Beth Israel Deaconess Medical Center, Boston, Mass; Brigham and Women’s Hospital (L.M., A.A.), Boston, Mass; Elyria Memorial Hospital (C.S.), Elyria, Ohio; Lubbock Heart Hospital (P.O.), Lubbock, Tex; Anderson Medical Center (B.M.L.), Anderson, SC; and Columbia University Medical Center (A.K., M.B.L.), New York, NY
| | - Martin B. Leon
- From the Department of Internal Medicine, Cardiology Divisions (J.J.P.) of the Beth Israel Deaconess Medical Center, Boston, Mass; Brigham and Women’s Hospital (L.M., A.A.), Boston, Mass; Elyria Memorial Hospital (C.S.), Elyria, Ohio; Lubbock Heart Hospital (P.O.), Lubbock, Tex; Anderson Medical Center (B.M.L.), Anderson, SC; and Columbia University Medical Center (A.K., M.B.L.), New York, NY
| |
Collapse
|
|
16
|
Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz RE. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006; 48:2440-7. [PMID: 17174180 DOI: 10.1016/j.jacc.2006.08.035] [Citation(s) in RCA: 300] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2006] [Revised: 08/07/2006] [Accepted: 08/07/2006] [Indexed: 11/18/2022]
Abstract
OBJECTIVES This trial examined the relative clinical efficacy, angiographic outcomes, and safety of zotarolimus-eluting coronary stents (ZES) with a phosphorylcholine polymer versus sirolimus-eluting stents (SES). BACKGROUND Whether a cobalt-based alloy stent coated with the novel antiproliferative agent, zotarolimus, and a phosphorylcholine polymer may provide similar angiographic and clinical benefit compared with SES is undetermined. METHODS A prospective, multicenter, 3:1 randomized trial was conducted to evaluate the safety and efficacy of ZES (n = 323) relative to SES (n = 113) in 436 patients undergoing elective percutaneous revascularization of de novo native coronary lesions with reference vessel diameters between 2.5 mm and 3.5 mm and lesion length > or =14 mm and < or =27 mm. The primary end point was 8-month angiographic in-segment late lumen loss. RESULTS Angiographic in-segment late lumen loss was significantly higher among patients treated with ZES compared with SES (0.34 +/- 0.44 mm vs. 0.13 +/- 0.32 mm, respectively; p < 0.001). In-hospital major adverse cardiac events were significantly lower among patients treated with ZES (0.6% vs. 3.5%, p = 0.04). In-segment binary angiographic restenosis was also higher in the ZES cohort (11.7% vs. 4.3%, p = 0.04). Total (clinically and non-clinically driven) target lesion revascularization rates at 9 months were 9.8% and 3.5% for the ZES and SES groups, respectively (p = 0.04). However, neither clinically driven target lesion revascularization (6.3% zotarolimus vs. 3.5% sirolimus, p = 0.34) nor target vessel failure (12.0% zotarolimus vs. 11.5% sirolimus, p = 1.0) differed significantly. CONCLUSIONS Compared with SES, treatment with a phosphorylcholine polymer-based ZES is associated with significantly higher late lumen loss and binary restenosis at 8-month angiographic follow-up. (The Endeavor III CR; http://clinicaltrials.gov/ct/show/NCT00265668?order=1?).
Collapse
Affiliation(s)
- David E Kandzari
- Duke Clinical Research Institute, Durham, North Carolina 27705, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
17
|
Holmes DR, Coolong A, O'Shaughnessy C, Chauhan M, Van Langenhove G, Hall P, Vermeersch P, Verlee P, Popma JJ, Cutlip D, Kuntz RE. Comparison of the CardioShield filter with the guardwire balloon in the prevention of embolisation during vein graft intervention: results from the CAPTIVE randomised trial. EUROINTERVENTION 2006; 2:161-168. [PMID: 19755255] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
AIMS This study assessed safety and efficacy of a third-generation distal protection device, MedNova CardioShield Bare Wire Myocardial Protection System, for treating Saphenous Vein Graft (SVG) disease.Treatment of SVG disease remains difficult, with increased adverse cardiac events (MACE) primarily manifested as no reflow and periprocedural infarction. Even with approved embolic protection devices, 30-day MACE rates are approximately 10%. METHODS AND RESULTS A multicentre randomized clinical trial evaluated a third-generation distal protection device MedNova CardioShield vs Percusurge GuardWire in 652 patients undergoing treatment of SVG disease, using a primary endpoint of 30-day death, Q-wave, non-Q-wave infarction, or target vessel revascularisation (MACE).The primary endpoint occurred in 11.4% with CardioShield vs 9.1% with GuardWire (P=.37). Intention-to-treat analysis showed a strong trend for noninferiority (P=.057). Secondary modified intention-to-treat analysis including only patients receiving treatment device and no protocol deviation (defined as treatment of another lesion not using embolic protection) supported noninferiority of CardioShield (P=.022). CONCLUSION Analysis of outcomes of treatment strategies for SVG disease is difficult. In this trial, final results depended on whether a patient actually received the device according to protocol. With 30-day MACE as primary endpoint, CardioShield was not demonstrated to be noninferior to GuardWire.
Collapse
Affiliation(s)
- David R Holmes
- Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
18
|
Pinto DS, Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Mehran R, Na Y, Turco M, Caputo R, Popma JJ, Cutlip DE, Russell ME, Cohen DJ. Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial. J Am Coll Cardiol 2006; 48:32-6. [PMID: 16814645 DOI: 10.1016/j.jacc.2006.02.060] [Citation(s) in RCA: 121] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/18/2005] [Revised: 02/22/2006] [Accepted: 02/28/2006] [Indexed: 12/18/2022]
Abstract
OBJECTIVES The objectives of the study were to evaluate the effect of angiographic follow-up on revascularization rates in the TAXUS-IV trial and to determine whether the relative benefit of paclitaxel-eluting stent implantation compared with bare metal stent implantation was modified by angiographic follow-up. BACKGROUND Although several clinical trials have demonstrated that drug-eluting stents (DES) reduce restenosis compared with bare-metal stents (BMS), virtually all of these studies have incorporated angiographic follow-up. METHODS In the TAXUS-IV trial, 1,314 percutaneous coronary intervention patients were randomized to receive paclitaxel-eluting stents (PES) (n = 662) or identical-appearing BMS (n = 652). Clinical outcomes were compared, stratified by assignment to angiographic follow-up or clinical follow-up alone. RESULTS Compared with clinical follow-up alone, angiographic follow-up patients had a significantly higher rate of target vessel revascularization (TVR) at 1 year (adjusted hazard ratio [HR] 1.46; p = 0.04), with similar relative increases in PES and BMS patients. Because PES reduced TVR by approximately 60% regardless of type of follow-up, assignment to angiographic follow-up tended to overestimate the absolute benefit of PES relative to clinical follow-up alone. In contrast, assessment of end points immediately before the time of follow-up angiography led to substantial underestimation of the absolute benefit of PES implantation. CONCLUSIONS Performance of mandatory angiographic follow-up increases rates of TVR among patients receiving both BMS and PES and overestimates the absolute clinical benefits of PES relative to clinical follow-up alone. Nonetheless, PES substantially reduces TVR regardless of assignment to mandatory angiographic follow-up or not. Future studies designed to determine the true clinical benefits of DES should either forgo routine angiographic follow-up or separate the time of repeat angiography from the primary clinical end point by as long as possible.
Collapse
Affiliation(s)
- Duane S Pinto
- Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
19
|
Hermiller J, Simonton C, Hinohara T, Mooney M, O'Shaughnessy C, Cannon L, Fletcher D, Zapien M, Chou T. Patient comfort with the StarClose Vascular Closure System: pain scale assessments from the CLIP study. Cardiovascular Revascularization Medicine 2006. [DOI: 10.1016/j.carrev.2006.03.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
|
20
|
Hermiller JB, Simonton C, Hinohara T, Lee D, Cannon L, Mooney M, O'Shaughnessy C, Carlson H, Fortuna R, Zapien M, Fletcher DR, DiDonato K, Chou TM. The StarClose® vascular closure system: Interventional results from the CLIP study. Catheter Cardiovasc Interv 2006; 68:677-83. [PMID: 17039508 DOI: 10.1002/ccd.20922] [Citation(s) in RCA: 89] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND The StarClose Vascular Closure System is a femoral access site closure technology that uses a flexible nitinol clip to complete a circumferential, extravascular arteriotomy close. The Clip CLosure In Percutaneous Procedures study was initiated to study the safety and efficacy of the StarClose device in subjects undergoing diagnostic and interventional catheterization procedures. METHODS A total of 17 U.S. sites enrolled 596 subjects, with 483 subjects randomized at a 2:1 ratio to receive StarClose or standard compression of the arteriotomy after the percutaneous procedure. The study included roll-in (n = 113), diagnostic (n = 208), and interventional (n = 275) arms with a primary safety endpoint of major vascular complications through 30 days and a primary efficacy endpoint of postprocedure time to hemostasis. RESULTS The results of the diagnostic StarClose cohort have been reported separately. Results for the interventional arm revealed major vascular complications occurring in 1.1% of StarClose subjects (2/184) and 1.1% in manual compression subjects (1/91; P = 1.00). No infections were seen in either cohort. Minor complications in the StarClose interventional group occurred at a rate of 4.3% (8/184) and with compression at 9.9% (9/91; P = 0.107). Pseudoaneurysm or arteriovenous fistula was not seen with StarClose. With StarClose, procedural success was 100% (136/136) for the diagnostic group and 98.9% (181/183) in the interventional group. Device success for the treatment group was 86.8%. In the interventional cohort, 87.3% (158/181) of StarClose subjects reported a pain scale of 0-3 compared with 93.3% (84/90) in the compression group, which was not statistically different. CONCLUSIONS The clinical results of this study demonstrate that the StarClose Vascular Closure System is noninferior to manual compression with respect to the primary safety endpoint of major vascular events in subjects who undergo percutaneous interventional procedures. StarClose significantly reduced time to hemostasis, ambulation, and dischargeability when compared with compression.
Collapse
|
|
21
|
Hermiller J, Simonton C, Hinohara T, Lee D, Cannon L, Mooney M, O'Shaughnessy C, Carlson H, Fortuna R, Yarbrough CA, Zapien M, Chou T. Clinical experience with a circumferential clip-based vascular closure device in diagnostic catheterization. J Invasive Cardiol 2005; 17:504-10. [PMID: 16204741] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
BACKGROUND The StarClose Vascular Closure System (Abbott Vascular Devices, Redwood City, California) utilizes a small, flexible nitinol clip to complete a circumferential, extravascular closure of the femoral arteriotomy site. The StarClose is an investigational device in the United States, limited by Federal law to investigational use. The StarClose is CE Mark approved. METHODS The CLIP study was a prospective, randomized, multicenter trial utilizing a noninferiority design to compare the rate of major vascular complications and time-to-hemostasis using the StarClose system versus manual compression. A total of 596 subjects were enrolled, 208 of whom underwent diagnostic angiography. This diagnostic subset is the focus of this report. The primary safety endpoint was major vascular complications and the primary efficacy endpoint was time-to-hemostasis. All patients were followed at 30 days with a clinical exam. RESULTS Subjects were randomized 2:1 to the StarClose (n = 136) or manual compression (n = 72). There were no major vascular complications in either group. Minor vascular complications occurred in 3 StarClose patients (2.2%), and 1 manual compression patient (1.4%) (p = 1.00). Use of the StarClose device reduced mean time-to-hemostasis from 15.47 +/- 11.4 to 1.46 +/- 4.5 minutes (p < 0.001) when compared to manual compression, and reduced the average time-to-ambulation from 269 +/- 135 to 163 +/- 105 minutes (p < or = 0.001). Device success was 94.1% (127/135), and procedural success was 100% (136/136). CONCLUSION The clinical results of this study concluded that the StarClose Vascular Closure System is noninferior to standard compression with respect to the the primary safety endpoint of closing arteriotomies in patients who undergo percutaneous diagnostic procedures.
Collapse
Affiliation(s)
- James Hermiller
- St. Vincent Hospital and Health Center, Indianapolis, Indiana, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
22
|
Weissman NJ, Koglin J, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Kutcher M, Wong SC, Strickland W, Mooney M, Russell ME, Ellis SG, Stone GW. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation. J Am Coll Cardiol 2005; 45:1201-5. [PMID: 15837249 DOI: 10.1016/j.jacc.2004.10.078] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2004] [Revised: 09/26/2004] [Accepted: 10/04/2004] [Indexed: 11/17/2022]
Abstract
OBJECTIVES The aim of this study was to use serial volumetric intravascular ultrasound (IVUS) to evaluate the effects of polymer-based, paclitaxel-eluting stents on in-stent neointima formation and late incomplete stent apposition. BACKGROUND The TAXUS-IV trial demonstrated that the slow-release, polymer-based, paclitaxel-eluting stent reduces angiographic restenosis and the need for repeat revascularization procedures. Serial IVUS studies reveal details of the pattern of vascular responses provoked by stent implantation that provide insight into device safety and efficacy. METHODS In the TAXUS-IV trial, patients were randomized to the slow-release, polymer-based, paclitaxel-eluting TAXUS stent or a bare-metal EXPRESS stent (Boston Scientific Corp., Natick, Massachusetts). As part of a formal substudy, complete volumetric IVUS data were available in 170 patients, including 88 TAXUS patients and 82 controls, at implantation and at nine-month follow-up. RESULTS No baseline differences were present in the clinical characteristics or IVUS parameters between the control and TAXUS groups. At nine-month follow-up, IVUS lumen volumes were larger in the TAXUS group (123 +/- 43 mm(3) vs. 104 +/- 44 mm(3), p = 0.005), due to a reduction in neointimal volume (18 +/- 18 mm(3) vs. 41 +/- 23 mm(3), p < 0.001). Millimeter-by-millimeter analysis within the stent demonstrated uniform suppression of neointimal growth along the entire stent length. Late lumen loss was similar at the proximal edge of the stent between the two groups, and reduced with the TAXUS stent at the distal edge (p = 0.004). Incomplete stent apposition at nine months was observed in only 3.0% of control and 4.0% of TAXUS stents (p = 0.12). CONCLUSIONS Polymer-based, paclitaxel-eluting TAXUS stents are effective in inhibiting neointimal tissue proliferation, and do not result in late incomplete stent apposition.
Collapse
|
|
23
|
Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38. [PMID: 15635110 DOI: 10.1056/nejmoa042000] [Citation(s) in RCA: 910] [Impact Index Per Article: 47.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Recent trials have demonstrated better outcomes with intensive than with moderate statin treatment. Intensive treatment produced greater reductions in both low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP), suggesting a relationship between these two biomarkers and disease progression. METHODS We performed intravascular ultrasonography in 502 patients with angiographically documented coronary disease. Patients were randomly assigned to receive moderate treatment (40 mg of pravastatin orally per day) or intensive treatment (80 mg of atorvastatin orally per day). Ultrasonography was repeated after 18 months to measure the progression of atherosclerosis. Lipoprotein and CRP levels were measured at baseline and follow-up. RESULTS In the group as a whole, the mean LDL cholesterol level was reduced from 150.2 mg per deciliter (3.88 mmol per liter) at baseline to 94.5 mg per deciliter (2.44 mmol per liter) at 18 months (P<0.001), and the geometric mean CRP level decreased from 2.9 to 2.3 mg per liter (P<0.001). The correlation between the reduction in LDL cholesterol levels and that in CRP levels was weak but significant in the group as a whole (r=0.13, P=0.005), but not in either treatment group alone. In univariate analyses, the percent change in the levels of LDL cholesterol, CRP, apolipoprotein B-100, and non-high-density lipoprotein cholesterol were related to the rate of progression of atherosclerosis. After adjustment for the reduction in these lipid levels, the decrease in CRP levels was independently and significantly correlated with the rate of progression. Patients with reductions in both LDL cholesterol and CRP that were greater than the median had significantly slower rates of progression than patients with reductions in both biomarkers that were less than the median (P=0.001). CONCLUSIONS For patients with coronary artery disease, the reduced rate of progression of atherosclerosis associated with intensive statin treatment, as compared with moderate statin treatment, is significantly related to greater reductions in the levels of both atherogenic lipoproteins and CRP.
Collapse
Affiliation(s)
- Steven E Nissen
- Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
|
24
|
Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O'Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, Stone GW, Leon MB, Knopf WD, O'Neill WW. Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions. Circulation 2004; 109:1948-54. [PMID: 15078794 DOI: 10.1161/01.cir.0000127129.94129.6f] [Citation(s) in RCA: 163] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Paclitaxel, a microtubule-stabilizing compound with potent antitumor activity, has been shown to inhibit smooth muscle cell proliferation and migration. The DELIVER trial was a prospective, randomized, blinded, multicenter clinical evaluation of the non-polymer-based paclitaxel-coated ACHIEVE stent compared with the stainless steel Multi-Link (ML) PENTA stent. METHODS AND RESULTS A total of 1043 patients with focal de novo coronary lesions, <25 mm in length, in 2.5- to 4.0-mm vessels were randomized (ACHIEVE n=524; ML PENTA n=519). Angiographic follow-up was performed in a subset of 442 patients (ACHIEVE n=228; ML PENTA n=214). Prespecified end points were a 40% reduction in target-vessel failure at 9 months (primary clinical end point) and a 50% reduction in binary restenosis at 8 months (major secondary end point). Baseline clinical characteristics were comparable between the groups. Patients in ACHIEVE had more type C lesions and a larger reference diameter. At follow-up, stent late loss was 0.81 versus 0.98 mm (P=0.003), stent binary restenosis was 14.9% versus 20.6% (P=0.076), and target-vessel failure was 11.9% versus 14.5% (P=0.12) for ACHIEVE and ML PENTA, respectively. CONCLUSIONS The ACHIEVE paclitaxel-coated stent decreased neointimal proliferation compared with the bare-metal PENTA stent; however, this reduction was insufficient to meet the prespecified primary end point of target-vessel failure and the secondary end point of binary restenosis.
Collapse
Affiliation(s)
- Alexandra J Lansky
- Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, 55 E 59th St, 6th Floor, New York, NY 10022-1112, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
25
|
Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109:1942-7. [PMID: 15078803 DOI: 10.1161/01.cir.0000127110.49192.72] [Citation(s) in RCA: 565] [Impact Index Per Article: 28.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The safety and efficacy of the slow-release, polymer-based, paclitaxel-eluting stent after implantation in a broad cross section of de novo coronary lesions at 1 year are unknown. METHODS AND RESULTS In the TAXUS-IV trial, 1314 patients with single de novo coronary lesions 10 to 28 mm in length, with reference-vessel diameter 2.5 to 3.75 mm, coverable by a single study stent, were prospectively randomized to the slow-release, polymer-based, paclitaxel-eluting TAXUS stent or an identical-appearing bare-metal EXPRESS stent. By actuarial analysis, the TAXUS stent compared with the bare-metal stent reduced the 12-month rates of target-lesion revascularization by 73% (4.4% versus 15.1%, P<0.0001), target-vessel revascularization by 62% (7.1% versus 17.1%, P<0.0001), target-vessel failure by 52% (10.0% versus 19.4%, P<0.0001), and composite major adverse cardiac events by 49% (10.8% versus 20.0%, P<0.0001). The 1-year rates of cardiac death (1.4% versus 1.3%), myocardial infarction (3.5% versus 4.7%), and subacute thrombosis (0.6% versus 0.8%) were similar between the paclitaxel-eluting and control stents, respectively. Between 9 and 12 months, there were significantly fewer myocardial infarctions (0% versus 1.1%, P=0.007), target-vessel revascularizations (2.4% versus 5.8%, P=0.002), and major adverse cardiac events (2.4% versus 6.3%, P=0.0009) in the paclitaxel-eluting stent than in the control stent group, respectively. CONCLUSIONS The relative efficacy reported at 9 months for the polymer-based, paclitaxel-eluting TAXUS stent compared with the EXPRESS stent is preserved and continues to increase at 1 year, with no safety concerns apparent.
Collapse
Affiliation(s)
- Gregg W Stone
- The Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, 55 E 59th St, 6th Floor, New York, NY 10022, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
26
|
Weissman NJ, Ellis S, Turco M, Greenberg J, Mann JT, Kutcher M, Chiu Wong S, O'Shaughnessy C, Russell M, stone GW. 1101-42 TAXUS IV: Results from the intravascular ultrasound substudy. J Am Coll Cardiol 2004. [DOI: 10.1016/s0735-1097(04)90274-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
|
27
|
Stone GW, Ellis SG, O'Shaughnessy C, Mann JT, Turco M, Raizner A, Cannon L, Kutcher M, Gurbel P, Wong S, Russell ME, Popma JJ. 843-4 Reduction in late loss and restenosis in patients with small vessels treated with the slow rate-release, polymer-based paclitaxel-eluting stent: Results from TAXUS-IV. J Am Coll Cardiol 2004. [DOI: 10.1016/s0735-1097(04)90363-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
|
28
|
Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350:221-31. [PMID: 14724301 DOI: 10.1056/nejmoa032441] [Citation(s) in RCA: 2035] [Impact Index Per Article: 101.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND Restenosis after coronary stenting necessitates repeated percutaneous or surgical revascularization procedures. The delivery of paclitaxel to the site of vascular injury may reduce the incidence of neointimal hyperplasia and restenosis. METHODS At 73 U.S. centers, we enrolled 1314 patients who were receiving a stent in a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm) in a prospective, randomized, double-blind study. A total of 652 patients were randomly assigned to receive a bare-metal stent, and 662 to receive an identical-appearing, slow-release, polymer-based, paclitaxel-eluting stent. Angiographic follow-up was prespecified at nine months in 732 patients. RESULTS In terms of base-line characteristics, the two groups were well matched. Diabetes mellitus was present in 24.2 percent of patients; the mean reference-vessel diameter was 2.75 mm, and the mean lesion length was 13.4 mm. A mean of 1.08 stents (length, 21.8 mm) were implanted per patient. The rate of ischemia-driven target-vessel revascularization at nine months was reduced from 12.0 percent with the implantation of a bare-metal stent to 4.7 percent with the implantation of a paclitaxel-eluting stent (relative risk, 0.39; 95 percent confidence interval, 0.26 to 0.59; P<0.001). Target-lesion revascularization was required in 3.0 percent of the group that received a paclitaxel-eluting stent, as compared with 11.3 percent of the group that received a bare-metal stent (relative risk, 0.27; 95 percent confidence interval, 0.16 to 0.43; P<0.001). The rate of angiographic restenosis was reduced from 26.6 percent to 7.9 percent with the paclitaxel-eluting stent (relative risk, 0.30; 95 percent confidence interval, 0.19 to 0.46; P<0.001). The nine-month composite rates of death from cardiac causes or myocardial infarction (4.7 percent and 4.3 percent, respectively) and stent thrombosis (0.6 percent and 0.8 percent, respectively) were similar in the group that received a paclitaxel-eluting stent and the group that received a bare-metal stent. CONCLUSIONS As compared with bare-metal stents, the slow-release, polymer-based, paclitaxel-eluting stent is safe and markedly reduces the rates of clinical and angiographic restenosis at nine months.
Collapse
Affiliation(s)
- Gregg W Stone
- Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute, New York 10022, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
29
|
Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-23. [PMID: 14523139 DOI: 10.1056/nejmoa035071] [Citation(s) in RCA: 3076] [Impact Index Per Article: 146.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
BACKGROUND Preliminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous coronary revascularization. METHODS We conducted a randomized, double-blind trial comparing a sirolimus-eluting stent with a standard stent in 1058 patients at 53 centers in the United States who had a newly diagnosed lesion in a native coronary artery. The coronary disease in these patients was complex because of the frequent presence of diabetes (in 26 percent of patients), the high percentage of patients with longer lesions (mean, 14.4 mm), and small vessels (mean, 2.80 mm). The primary end point was failure of the target vessel (a composite of death from cardiac causes, myocardial infarction, and repeated percutaneous or surgical revascularization of the target vessel) within 270 days. RESULTS The rate of failure of the target vessel was reduced from 21.0 percent with a standard stent to 8.6 percent with a sirolimus-eluting stent (P<0.001)--a reduction that was driven largely by a decrease in the frequency of the need for revascularization of the target lesion (16.6 percent in the standard-stent group vs. 4.1 percent in the sirolimus-stent group, P<0.001). The frequency of neointimal hyperplasia within the stent was also decreased in the group that received sirolimus-eluting stents, as assessed by both angiography and intravascular ultrasonography. Subgroup analyses revealed a reduction in the rates of angiographic restenosis and target-lesion revascularization in all subgroups examined. CONCLUSIONS In this randomized clinical trial involving patients with complex coronary lesions, the use of a sirolimus-eluting stent had a consistent treatment effect, reducing the rates of restenosis and associated clinical events in all subgroups analyzed.
Collapse
Affiliation(s)
- Jeffrey W Moses
- Cardiovascular Research Foundation and Lenox Hill Heart and Vascular Institute of New York, New York 10021, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
30
|
Baim DS, Flatley M, Caputo R, O'Shaughnessy C, Low R, Fanelli C, Popma J, Fitzgerald P, Kuntz R. Comparison of PRE-dilatation vs direct stenting in coronary treatment using the Medtronic AVE S670 Coronary Stent System (the PREDICT trial). Am J Cardiol 2001; 88:1364-9. [PMID: 11741553 DOI: 10.1016/s0002-9149(01)02114-2] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Current stent delivery systems make primary stenting (stent placement without predilatation) possible, but few controlled trials have been performed to evaluate the success, safety, cost saving, and potential benefit of this approach in reducing late restenosis. The Comparison of PRE-Dilatation Versus Direct Stenting In Coronary Treatment using the Medtronic AVE S670 Coronary Stent System trial was a 399-patient study comparing results with the Medtronic-AVE S670 stent to objective performance criteria based on prior approved stents, with subrandomization to direct stenting versus stenting after balloon predilatation. Overall, results with the S670 stent showed excellent success and safety, with delivery success of 99%, a 14-day adverse event rate of 6.8% (including 6.5% non-Q-wave myocardial infarction), and favorable angiographic (20%) and clinical (12%) restenosis rates. Direct stenting was successful in 92% of cases, with a 99.5% secondary success rate including additional pretreatment of initially unsuccessful direct-stenting attempts, and no increase in complications. There were modest ( approximately 10%) savings in fluoroscopy time, contrast use, and a decrease in angioplasty balloon use (0.6 vs 1.3 balloons/case), but no reduction in clinical or angiographic restenosis. Patients treated later in the study, with a device that had less balloon extension beyond the edges of the stent, had slightly lower angiographic restenosis rates (19% vs 23%). In conclusion, the S670 stent showed excellent overall performance. Although direct stenting was safe and highly successful, it offered only modest cost savings, and no reduction in late restenosis compared with stenting after predilatation.
Collapse
Affiliation(s)
- D S Baim
- Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
|
31
|
Rees S, Martin DP, Scott SV, Brown SH, Fraser N, O'Shaughnessy C, Beresford IJ. Development of a homogeneous MAP kinase reporter gene screen for the identification of agonists and antagonists at the CXCR1 chemokine receptor. J Biomol Screen 2001; 6:19-27. [PMID: 11679162 DOI: 10.1177/108705710100600104] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Agonist activity at G protein-coupled receptors (GPCRs) that regulate heterotrimeric G proteins of the Galpha(i/o) or Galpha(q) families has been shown to result in activation of the mitogen-activated protein (MAP) kinase cascade. To facilitate compound screening for these classes of GPCR, we have developed a reporter gene that detects the activation of the ternary complex transcription factor Sap1a following MAP kinase activation. In contrast to other reporter gene assays for Galpha(i/o)-coupled GPCRs, the MAP kinase reporter generates an increase in signal in the presence of agonist. The reporter gene has been transfected into Chinese hamster ovary cells to generate a "host" reporter gene-containing cell line. The Galpha(i)-coupled human CXCR1 chemokine receptor was subsequently transfected into this cell line in order to develop a 384-well format screen for both agonists and antagonists of this receptor. Agonists activated the reporter gene with the expected rank order of potency and with similar concentration dependence as seen with the regulation of other signal transduction cascades in mammalian cells: interleukin-8 (IL-8) (pEC(50) = 7.0 +/- 0.1) > GCP-2 (pEC(50) = 6.3 +/- 0.1) > NAP-2 (pEC(50) < 6). CXCR1-mediated activation of MAP kinase was inhibited by pertussis toxin and the MEK inhibitor PD98059, demonstrating that receptor activation of MAP kinase is due to pertussis toxin-sensitive Galpha(i/o)-family G proteins to cause the activation of MEK kinase. Using the 384-well format, assay performance was unaffected by solvent concentrations of 0.5% ethanol, 0.15% glycerol, or 1% DMSO. Signal crosstalk between adjacent wells was less than 1%. The assay exhibited a Z factor of 0.53 and a coefficient of variation of response to repeated application of IL-8 (100 nM) of 15.9%.
Collapse
Affiliation(s)
- S Rees
- Molecular Discovery Research Unit, Glaxo Wellcome Medicines Research Centre, Hertfordshire, UK.
| | | | | | | | | | | | | |
Collapse
|
|
32
|
Kereiakes D, Linnemeier TJ, Baim DS, Kuntz R, O'Shaughnessy C, Hermiller J, Fink S, Lansky A, Nishimura N, Broderick TM, Popma J. Usefulness of stent length in predicting in-stent restenosis (the MULTI-LINK stent trials). Am J Cardiol 2000; 86:336-41. [PMID: 10922447 DOI: 10.1016/s0002-9149(00)00928-0] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The cumulative experience of 4 clinical trials using the MULTI-LINK coronary stent design was analyzed. Multivariable logistic regression identified postprocedure in-stent minimum lumen diameter (p = 0.0001), stent length (p = 0.0038), smoking (p = 0.0105). and diabetes (p = 0.0803) as the most important predictors of in-stent restenosis at late (6- to 9-month) angiographic follow-up.
Collapse
Affiliation(s)
- D Kereiakes
- The Carl and Edith Lindner Center for Research and Education, Cincinnati, Ohio 45219, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
33
|
Kereiakes DJ, Midei M, Hermiller J, O'Shaughnessy C, Schlofmitz R, Yakubov S, Fink S, Hu F, Nishimura N, Sievers M, Valentine ME, Broderick T, Lansky A, Moses J. Procedural and late outcomes following MULTI-LINK DUET coronary stent deployment. Am J Cardiol 1999; 84:1385-90. [PMID: 10606109 DOI: 10.1016/s0002-9149(99)00581-0] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The MULTI-LINK DUET is the next generation MULTI-LINK stent with modified strut geometry. Safety and efficacy of the MULTI-LINK DUET were evaluated in a prospective multicenter registry and were compared with prior MULTI-LINK stent experience from the ASCENT randomized trial. A total of 270 patients received 302 MULTI-LINK DUET stents and were evaluated using a composite primary end point of major cardiac events (death, Q-wave and non-Q-wave myocardial infarction, and requirement for coronary revascularization) attributable to the target stenosis cumulative to 30 days following enrollment. Quantitative coronary angiography was performed at a mean follow-up of 6 +/- 2 (+/-SD) months. No difference in primary end point or in angiographic restenosis to 6 months was observed between MULTI-LINK DUET and MULTI-LINK experiences. The MULTI-LINK DUET demonstrated improved device and procedural success, less postprocedural in-stent stenosis, larger postprocedural minimal lumen diameter, and fewer postprocedural marginal dissections compared with the MULTI-LINK stent. Multivariate regression modeling identified stent length, diabetes mellitus, poststent minimal lumen diameter, lesion eccentricity, and current smoking as independent predictors of in-stent restenosis. Thus, the MULTI-LINK DUET Registry demonstrates enhanced procedural performance with clinical and angiographic outcomes similar to those previously observed for the MULTI-LINK stent in the ASCENT randomized trial.
Collapse
Affiliation(s)
- D J Kereiakes
- Linder Research Center, Cincinnati, Ohio 45219, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
|
34
|
Webb SE, Fowler RE, O'Shaughnessy C, Pinder JC, Dluzewski AR, Gratzer WB, Bannister LH, Mitchell GH. Contractile protein system in the asexual stages of the malaria parasite Plasmodium falciparum. Parasitology 1996; 112 ( Pt 5):451-7. [PMID: 8677134 DOI: 10.1017/s0031182000076915] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
F-actin was detected in asexual-stage Plasmodium falciparum parasites by fluorescence microscopy of blood films stained with fluorescent phalloidin derivatives. F-actin was present at all stages of development and appeared diffusely distributed in trophic parasites, but merozoites stained strongly at the poles and peripheries. No filament bundles could be discerned. A similar distribution was obtained by immunofluorescence with 2 polyclonal anti-actin antibodies, one of which was directed against a peptide sequence present only in parasite actin (as inferred from the DNA sequence of the gene). A monoclonal anti-actin antibody stained very mature or rupturing schizonts but not immature parasites. Myosin was identified in immunoblots of parasite protein extracts by several monoclonal anti-skeletal muscle myosin antibodies, as well as by a polyclonal antiserum directed against a consensus conserved myosin sequence (IQ motif). The identity of the polypeptides recognised by these antibodies was confirmed by overlaying blots with biotinylated F-actin. The antiserum and one of the monoclonal antibodies were used in immunofluorescence studies and were found to stain all blood-stage parasites, with maximal intensity towards the poles of merozoites. Our results are consistent with the presence of an actomyosin motor system in the blood-stage malaria parasite.
Collapse
Affiliation(s)
- S E Webb
- Department of Immunology, UMDS, Medical School, Guy's Hospital, London, UK
| | | | | | | | | | | | | | | |
Collapse
|
|
35
|
Boschert U, O'Shaughnessy C, Dickinson R, Tessari M, Bendotti C, Catsicas S, Pich EM. Developmental and plasticity-related differential expression of two SNAP-25 isoforms in the rat brain. J Comp Neurol 1996; 367:177-93. [PMID: 8708003 DOI: 10.1002/(sici)1096-9861(19960401)367:2<177::aid-cne2>3.0.co;2-2] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
In this article we study the relationship between the expression pattern of two recently identified isoforms of the 25-kD synaptosomal-associated protein (SNAP-25a and SNAP-25b) and the morphological changes inherent to neuronal plasticity during development and kainic acid treatment. SNAP-25 has been involved in vescicle fusion in the nerve terminal, and most likely participates in different membrane fusion-related processes, such as those involved in neurotransmitter release and axonal growth. In the adult brain, SNAP-25b expression exceeded SNAP-25a in distribution and intensity, being present in most brain structures . Moderate or high levels of SNAP-25a hybridization signal were found in neurons of the olfactory bulb, the layer Va of the frontal and parietal cortices, the piriform cortex, the subiculum and the hippocampal CA4 field, the substantia nigra/pars compacta, and the pineal gland, partially overlapping SNAP-25b mRNA distribution. In restricted regions of cerebral cortex, thalamus, mammillary bodies, substantia nigra, and pineal glands the two isoforms were distributed in reciprocal fashion. During development SNAP-25a mRNA was the predominant isoform, whereas SNAP-25b expression increased postnatally. The early expression of SNAP-25a in the embryo and the decrease after P21 is suggestive of a potential involvement of this isoform in axonal growth and/or synaptogenesis. This conclusion is indirectly supported by the observation that SNAP-25a mRNA, but not SNAP-25b mRNA, was upregulated in the granule cells of the adult dentate gyrus 48 hours after kainate-induced neurotoxic damage of the hippocampal CA3-CA4 regions. Increase of SNAP-25 immunoreactivity was observed as early as 4 days after kainate injection within the mossy fiber terminals of the CA3 region, and in the newly formed mossy fiber aberrant terminals of the supragranular layer. These data suggest an isoform-specific role of SNAP-25 in neural plasticity.
Collapse
Affiliation(s)
- U Boschert
- Glaxo Institute for Molecular Biology, Geneva, Switzerland.
| | | | | | | | | | | | | |
Collapse
|
|
36
|
O'Shaughnessy C, Prosser E, Keane T, O'Neill L. Differential stimulation of IL-6 secretion following apical and basolateral presentation of IL-1 on epithelial cell lines. Biochem Soc Trans 1996; 24:83S. [PMID: 8674764 DOI: 10.1042/bst024083s] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- C O'Shaughnessy
- Elan Corporation Research Institute, Trinity College, Dublin 2, Ireland
| | | | | | | |
Collapse
|
|
37
|
MacNamara P, O'Shaughnessy C, Manduca P, Loughrey HC. Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures. Calcif Tissue Int 1995; 57:436-41. [PMID: 8581876 DOI: 10.1007/bf00301947] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Expression of progesterone receptors (PR) was studied in human osteoblast-like cell lines and primary human osteoblast cultures at the molecular level. Using the sensitive reverse transcriptase polymerase chain reaction (RT-PCR) and oligonucleotide primers which flank the progesterone-binding domain of human PR, progesterone receptor (PR) mRNA was detected in three osteoblast-like cell lines--HOS-TE85, MG-63, and SAOS-2. When compared with beta-actin gene expression, levels of PRmRNA transcripts varied between cell lines (PRmRNA in HOS-TE85 > MG-63 >> SAOS-2). In addition, RT-PCR confirmed the presence of PRmRNA transcripts in primary human osteoblast cells cultured from collagenase-treated bone. Immunostaining was used to visualize PR protein in cells. All osteoblast-like cell lines showed specific staining for PR. Immunoreactivity was distributed equally in the nucleus and cytoplasm. The level of staining was significantly lower than that detected in PR-positive MCF-7 breast cancer cells though well above background levels obtained for PR-negative HeLa cells. The finding that PR is expressed at both the level of mRNA and protein in several osteoblast-like cell lines as well as in human primary osteoblast cultures indicates that bone-forming osteoblast cells are direct targets for progesterone action.
Collapse
Affiliation(s)
- P MacNamara
- Department of Biochemistry, University College Galway, Ireland
| | | | | | | |
Collapse
|
|
38
|
|
|
39
|
O'Shaughnessy C, Bhoola KD. Comparison of the action of cholecystokinin, carbachol and vasoactive intestinal peptide on receptor-activated formation of cyclic GMP and cyclic AMP in the striatum and the pancreas. Biochem Pharmacol 1986; 35:4049-52. [PMID: 3022747 DOI: 10.1016/0006-2952(86)90026-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Sulphated cholecystokinin octapeptide (CCK-8S) and sodium nitroprusside (SNP) increased the formation of cyclic GMP in rat striatal slices with no effect on cyclic AMP. CCK-8S, SNP and carbachol increased the formation of cyclic GMP in guinea-pig pancreatic lobules, but had no effect on levels of cyclic AMP. Vasoactive intestinal peptide (VIP) significantly stimulated the formation of cyclic AMP in both striatal and pancreatic tissue without effect on levels of cyclic GMP in these tissues. In rat striatal slices carbachol significantly inhibited the VIP-stimulated increase in cyclic AMP.
Collapse
|
|
40
|
Abstract
In the rat striatum sulphated CCK8 has no significant effect on equilibrium binding of 3H-spiperone but has a considerable, although transient, effect under non-equilibrium conditions. Under non-equilibrium conditions (during the association phase of ligand binding) and at high ligand concentrations (1 nM), CCK8 displaces specific binding and at low ligand concentrations (0.1 nM) CCK8 enhances specific binding. CCK8 has no effect on 3H-spiperone dissociation kinetics.
Collapse
|
|
41
|
Abstract
Rats were given powdered diet containing L-DOPA (together with the peripheral decarboxylase inhibitor carbidopa) for a period of 6 months. The estimated daily intake was in the range 20-30 mg/kg. Initially, at 1 week and 1 month, L-DOPA-fed rats exhibited enhanced spontaneous locomotor activity, but this fell to within the control range by 3 and 6 months, although (+)-amphetamine-induced hyperactivity was greater at 6 months in L-DOPA-treated animals than in control rats. Six months after receiving L-DOPA in their diet rats showed enhanced stereotypy scores to a series of dopamine agonists administered acutely including (+)-amphetamine, nomifensine, L-DOPA, apomorphine and piribedil compared with the control animals. In another behaviour test L-DOPA administration reduced the cataleptic potency of both fluphenazine and haloperidol was increased. Biochemically 6 months treatment of rats with L-DOPA was associated with significantly increased plasma concentrations of L-DOPA, enhanced striatal levels of L-DOPA, dopamine and dopamine metabolites, enhanced specific binding (as indicated by increased Bmax values) of [3H] spiroperidol, [3H] ADTN and [3H] 5-HT to striatal membranes, and increased basal and dopamine-stimulated striatal adenylate cyclase activity. The results are discussed in the light of changes of sensitivity of cerebral dopamine receptors, an increase in receptor numbers, and the tolerance to L-DOPA which often develop in the treatment of Parkinson's disease.
Collapse
|
|
42
|
O'Shaughnessy C. Diary of an angry nurse practitioner. Am J Nurs 1976; 76:1165-8. [PMID: 1047614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
|
43
|
O'Shaughnessy C. New role: nurse-associate in general practice. RN 1973; 36:44-5 passim. [PMID: 4489307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|